The startup’s first disease target is chronic inflammatory demyelinating polyneuropathy (CIDP), which can be treated with a blockbuster Argenx drug. Nuvig aims to show its drug can offer a better way to treat this disease and other autoimmune conditions.
The post Nuvig Therapeutics Nabs $161M to Build Case for a Better Approach to Autoimmune Disease appeared first on MedCity News.
